Werewolf Therapeutics (HOWL) Revenue (2022 - 2026)

Werewolf Therapeutics (HOWL) has reported Revenue for 4 consecutive years, with $21.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue changed N/A year-over-year to $21.0 million in Q2 2026; TTM through Jun 2026 was $21.0 million, a 139900.0% increase from a year earlier, with the FY2024 full-year figure at $1.9 million, down 90.47% from the prior year.
• Revenue was $21.0 million for Q2 2026 at Werewolf Therapeutics, up from $15000.0 in the prior quarter.
• Over five years, Revenue peaked at $21.0 million in Q2 2026 and troughed at $15000.0 in Q4 2024.
• A 4-year average of $5.4 million and a median of $4.5 million in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue jumped 94.82% in 2023 and plunged 99.0% in 2024, its largest moves.
• Over 4 years, Revenue stood at $7.3 million in 2022, then plunged by 79.39% to $1.5 million in 2023, then sank by 99.0% to $15000.0 in 2024, then surged by 139900.0% to $21.0 million in 2026.
• The last three Revenue figures came in at $21.0 million (Q2 2026), $15000.0 (Q4 2024), and $1.1 million (Q2 2024), per Business Quant data.